Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy

Archives of Neurology

Volumn 59, Issue 5, 2002, Pages 751-757

  Sharma, Khema R ^a   Cross, John ^a   Ayyar, D Ram ^a   Martinez Arizala, Alberto ^a   Bradley, Walter G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INSULIN; ORAL ANTIDIABETIC AGENT; PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DEMYELINATION; DIABETIC NEUROPATHY; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; KIDNEY DYSFUNCTION; MALE; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMAPHERESIS; PRIORITY JOURNAL;

EID: 0036091494     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.5.751     Document Type: Article

References (44)

1. Incidence of diabetic neuropathy which fulfills electrophysiological criteria of CIDP
2. Prevalence of chronic inflammatory demyelinating polyneuropathy-like syndrome in diabetes mellitus
3. Demyelinating neuropathy in diabetes mellitus
4. Pathologic alterations in the diabetic neuropathies of humans: A review
5. Autoantibodies to nervous tissue structures are associated with autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus
6. Anti-sympathetic nervous system autoantibodies: Diminished catacholamines with orthostasis
7. Class II antigen expression in peripheral neuropathies
8. Diabetic peripheral neuropathy: A clinicopathologic and immunohistochemical analysis of sural nerve biopsies
9. Autoimmune diabetic neuropathy
10. Chronic inflammatory demyelinating polyneuropathy in diabetics: Motor conductions are important in differential diagnosis with diabetic polyneuropathy
11. Subacute diabetic proximal neuropathy
12. Chronic inflammatory demyelinating polyneuropathy with only sensory symptoms (CIDPS): Electroneurophysiological and morphological aspects and association with diabetes mellitus
13. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy
14. Root stimulation improves the detection of acquired demyelinating polyneuropathies
15. Oemyelinating neuropathy in patients with type II diabetes
16. Oemyelinating motor neuropathy inpatients with diabetic polyneuropathy
17. Some polyneuropathies (PNS) in insulin-requiring adult-onset diabetes (IRAOD) can benefit remarkably from antidysimmune treatment
18. The spectrum of chronic inflammatory demyelinating polyneuropathy
19. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy
20. Successful treatment of neuropathies inpatients with diabetes mellitus
21. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics
22. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome
23. A controlled trial of high-dose intravenous immune globulin infusions as a treatment for dermatoyositis
24. Plasma exchange versus immunoglobulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
25. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study
26. Intravenous immunoglobulin in untreated patients with chronic inflammatory demyelinating polyneuropathy
27. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)
28. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
29. Consensus criteria for the diagnosis of partial conduction block
30. A computer simulation of conduction block: Effects produced by actual block versus interphase cancellation
31. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy
32. Chronic inflammatory demyelinating polyradiculoneuropathy: Clinical characteristics, course, and recommendations for diagnostic criteria
33. Variables influencing neuropathic end points: The Rochester Diabetic Neuropathy Study ot Healthy Subjects
34. Meaningful degree of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy
35. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society
36. On the mechanisms of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy
37. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues
38. Mechanisms of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases
39. Macrophage responses and myelin clearance during Wallerian degeneration: Relevance to immune-mediated demyelination
40. Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis
41. Human immunogloblin preparations for intravenous use (IVIg) prevent experimental autoimmune uveoretinitis
42. Human IgG Fc receptors
43. High-dose intravenous IgG treatment and renal function
44. Effect of high-dose intravenous immunoglobulin therapy on blood rheology